Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Contribution of Host miRNA-223-3p to SARS-CoV-Induced Lung Inflammatory Pathology

  • Morales, Lucía
  • Oliveros, Juan C.
  • Enjuanes Sánchez, Luis
  • Solá Gurpegui, Isabel
Severe acute respiratory syndrome coronavirus (SARS-CoV) and the closely related SARS-CoV-2 are emergent highly pathogenic human respiratory viruses causing acute lethal disease associated with lung damage and dysregulated inflammatory responses. SARS-CoV envelope protein (E) is a virulence factor involved in the activation of various inflammatory pathways. Here, we study the contribution of host miRNAs to the virulence mediated by E protein. Small RNAseq analysis of infected mouse lungs identified miRNA-223 as a potential regulator of pulmonary inflammation, since it was significantly increased in SARS-CoV-WT virulent infection compared to the attenuated SARS-CoV-DE infection. In vivo inhibition of miRNA-223-3p increased mRNA levels of pro-inflammatory cytokines and NLRP3 inflammasome, suggesting that during lung infection, miRNA-223 might contribute to restrict an excessive inflammatory response. Interestingly, miRNA-223-3p inhibition also increased the levels of the CFTR transporter, which is involved in edema resolution and was significantly downregulated in the lungs of mice infected with the virulent SARS-CoV-WT virus. At the histopathological level, a decrease in the pulmonary edema was observed when miR-223-3p was inhibited, suggesting that miRNA-223-3p was involved in the regulation of the SARS-CoVinduced inflammatory pathology. These results indicate that miRNA-223 participates in the regulation of E protein-mediated inflammatory response during SARS-CoV infection by targeting different host mRNAs involved in the pulmonary inflammation, and identify miRNA-223 as a potential therapeutic target in SARS-CoV infection. IMPORTANCE The SARS-CoV-2 pandemic has emphasized the need to understand the mechanisms of severe lung inflammatory pathology caused by human deadly coronaviruses in order to design new antiviral therapies. Here, we identify miRNA-223-3p as a host miRNA involved in the regulation of lung inflammatory response mediated by envelope (E) protein during SARS-CoV infection. miRNAs downregulate the expression of cellular mRNAs and participate in complex networks of mRNA–miRNA interactions that regulate cellular processes. The inhibition of miRNA-223 in infected mice by intranasal administration of antisense RNAs led to changes in the expression of host factors involved in inflammation (cytokines, chemokines, and NLRP3 inflammasome) and in the resolution of lung edema ion transporter CFTR. These results confirmed the contribution of miRNA-223 to the regulation of SARS-CoV-induced pathogenic processes and support the therapeutic potential of inhibiting miRNAs during coronavirus infection using RNA interference approaches., This work was supported by grants from the Government of Spain (BIO2016-75549-R; PID2019-107001RBI00 AEI/FEDER, UE; SEV 2017-0712 and PIE_INTRAMURAL_LINEA 1-202020E079), CSIC (PIE_INTRAMURAL -202020E043), the European Zoonotic Anticipation and Preparedness Initiative (ZAPI) (IMI_JU_115760), the European Commission (H2020-SC1-2019, ISOLDA Project No. 848166-2), and the U.S. National Institutes of Health (NIH) (2P01AI060699). L.M. received a fellowship from the Ministry of Science an Innovation of Spain (BIO2010-16705) and a contract from ZAPI., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SARS-CoV-2-derived RNA replicons as safe and effective vaccines

  • Villarejo-Torres, Marta
  • Nombela, Iván
  • Muñoz-Santos, Diego
  • Ruiz-Yuste, Mercedes
  • Marchena-Pasero, Ana
  • Rueda-Huélamo, María
  • Ripoll-Gómez, Jorge
  • Sánchez-Cordón, Pedro J.
  • Fernández del Ama, Laura
  • Honrubia, José M.
  • Gutiérrez Álvarez, Javier
  • Hurtado Tamayo, Jesús
  • Requena-Platek, Ricardo
  • Guzmán, María
  • Casasnovas, José María
  • García-Arriaza, Juan
  • Pérez, Patricia
  • Martín-Jouve, Beatriz
  • Matamoros Grande, Tania
  • Pintado, Belén
  • Perlman, Stanley
  • Solá Gurpegui, Isabel
  • Zúñiga Lucas, Sonia
  • Enjuanes Sánchez, Luis
A collection of RNA replicons (RRs) derived from severe acute respiratory syndrome 2 (SARS-CoV-2) for use in vaccine design was constructed by genetic engineering using bacterial artificial chromosomes. A replicon, which was deleted in six genes (3a, 3c, E, 6, 7a, and 7b) was selected. Cells infected with the RR vaccine candidate led to the formation of virus-like particles that, due to the failure of being secreted, increase vaccine safety, in contrast to the wild type virions. The replicon maintained the production of RNAs encoding at least proteins S, M, and N for several days. Intranasal immunization with the RR of transgenic mice, expressing human ACE2, elicited respiratory mucosal immunity. Immunization protected against challenge with SARS-CoV-2, inducing IgG, IgM, and IgA antibodies to the spike (S) protein, the receptor binding domain, N and M proteins, and cellular immune responses (CD4+, CD8+, and long-term memory T cells). Coinfection of cells with the RR vaccine and a full-length SARS-CoV-2 led to a significant inhibition of replication of full-length virus, increasing the safety of the RR vaccine. The RR vaccine induced a minor inflammatory reaction in the absence of major side effects and was stable at different temperatures. An updated RR expressing XBB.1.5 S protein elicited neutralizing antibodies against the homologous virus and provided full protection against recent SARS-CoV-2 variants., This work was supported by grants from the Government of Spain (PID2022-140328OB-I00, MCIN/AEI/10.13039/501100011033/FEDER, UE; PID2019-107001RB-I00 AEI/FEDER), the Community of Madrid (Y2020/BIO- 6576, COVID-PREclinical-MODels-CM) Spain, the European Commission (H2020-SC1-2019, ISOLDA Project No. 848166-2), and NIH, project P01 AI060699/AI/NIAID NIH HHS/United States. J.M.H. and D.M.-S. received a contract from Community of Madrid (Y2020/BIO- 6576, COVID-PREclinical-MODels-CM). I.N.-D., M.R.-Y., M.A.R.-H., and J.R.-G. received a contract from CSIC. M.V.-T. received a predoctoral contract (FPU21/02704) for the Training of University Teachers from Government of Spain. J.M.H. received a fellowship from MCIN/ AEI/FEDER, Ref. PID2019-107001RB-I00UE. A.M.-P. received a fellowship Ref. PREP2022-0005777 from PID2022-140328OB-I00 MCIN/AEI/10.13039/ 501100011033/ FEDER, UE, RR received a fellowship from Arnhold de la Camara Foundation, Spain, and MG received a predoctoral contract (PIPF-2022/SAL-GL-24549) from Community of Madrid, Spain., Peer reviewed